Recently, two following demographic trends have been clearly observed in the world: population aging and an increase in the prevalence of obesity. In February 2022, the European Society for Clinical Nutrition and Metabolism (ESPEN) and the European Association for the Study of Obesity (EASO) published the first consensus guidelines for the definition and diagnosis of sarcopenic obesity, which characterizes by a combination of excess adipose tissue with a decrease in muscle mass, muscle strength and impaired muscle function. The purpose of this review is to describe the prevalence, the main etiopathogenetic factors of sarcopenic obesity, as well as currently accepted approaches to the diagnosis of this condition.
18 October 2025 in Primary Health Care (Russian Federation)
These guidelines describe the management of follow-up monitoring of patients with gastritis and duodenitis. They include the approximate scope and frequency of paraclinical investigations, as well as information on the diagnosis, treatment, and prevention of complications. The guidelines are intended for general practitioners, family doctors, as well as for mid-level health providers working with the above-mentioned doctors, for paramedics performing the doctor functions. These guidelines can be used by healthcare executives, heads of primary care facilities, and their departments.
27 February 2025 in Russian Journal of Preventive Medicine
Objective. To characterize and compare myokine profiles in patients with obesity depending on the presence of sarcopenia. Materials and Methods. The study included 77 patients with obesity examined at the National Medical Research Center for Therapy and Preventive Medicine of the Ministry of Health of Russia from January 2023 to April 2024. Sarcopenia was diagnosed using criteria including handgrip strength, skeletal muscle mass, and physical function assessment. Serum erythroferrone, irisin, myostatin, and interleukin (IL)-6 were assessed using enzyme-linked immunosorbent assay. Results. Thirteen (16.9%) patients demonstrated reduced handgrip strength; 22 participants had decreased appendicular muscle mass to body mass (AMM/BM) ratio. The AMM value correlated with serum concentrations of irisin (ρ=0.297; p<0.009) and erythroferrone (ρ=0.229; p<0.045). Serum concentrations of irisin significantly differed depending on the handgrip strength on the dominant hand (p=0.038), AMM value (p=0.036), and appendicular muscle mass index (ASMI, p=0.007). Serum concentrations of IL-6 were higher in patients with obesity and impaired muscle function (slower 4 m walking speed, p=0.073). Conclusion. In patient with obesity, sarcopenia is associated with myokine profile alterations. This could be due to the disrupted structure, reduced quantity, and disturbed function of muscles in sarcopenia.
23 April 2024 in Russian Journal of Preventive Medicine
Sarcopenic obesity is a condition characterized by excessive fat tissue accumulation in the body accompanied by reduced skeletal muscle mass and muscle strength. The definition of this state remains the subject of discussion. For example, there is no consensus among scientists and clinicians on whether only patients with reduced absolute skeletal muscle mass must be attributed to the category of individuals with sarcopenic obesity, or patients with obesity and a reduced proportion of skeletal muscles in the body should also be included in this category. Despite disagreements, it is clear that sarcopenic obesity is a particular, distinct nosological entity. Its defining feature is that compared to sarcopenia and obesity as separate diseases sarcopenic obesity is characterized by a much higher risk of complications, in particular type 2 diabetes mellitus, non-alcoholic fatty liver disease, chronic kidney disease, as well as by a more unfavorable prognosis. In addition, the process of body mass decrease, which often leads to additional loss of skeletal muscle mass, can be associated with an increased risk of decompensation of comorbidities and adverse outcomes due to the initially lower skeletal muscle mass in the body. In this review, we will elaborate on the interrelation between sarcopenic obesity and some of the most common and significant diseases associated with metabolic disorders as well as describe the probable mechanisms underlying this interrelation.
28 July 2025 in Russian Journal of Preventive Medicine
Objective. To study the associations of the sarcopenia index with body composition parameters, strength, and skeletal muscle function in patients with non-alcoholic fatty liver disease. Materials and methods. The study included 130 patients with non-alcoholic fatty liver disease (NAFLD) who presented to the National Medical Research Center for Therapy and Preventive Medicine from February 2023 to December 2024. The diagnosis of sarcopenia was made based on measuring grip strength and skeletal muscle mass according to dual-energy X-ray absorptiometry data and assessing physical functioning. The serum cystatin C was measured using an enzyme-linked immunosorbent assay. Results. The median age of patients was 56.5 (47—64) years, and 58.5% were females (n=76). Thirty-eight (29.2%) NAFLD patients enrolled in the study had dynapenia, and 10 (7.7%) had sarcopenia. In patients with NAFLD and dynapenia or sarcopenia, the sarcopenia index values were significantly lower than in patients with NAFLD without dynapenia or sarcopenia (p=0.025 vs. p=0.037, respectively). In addition, the values of the sarcopenia index were significantly correlated with muscle strength and muscle function indicators (grip strength r=0.282; p=0.002; 4 meter gait speed r=–0.361; p<0.001). In accordance with the results of the ROC analysis, the values of the area under the ROC curve (AUROC) for the detection of a case of dynapenia or sarcopenia were 0.639 (p=0.025) and 0.663 (p=0.037), respectively, indicating the average quality of the model. Conclusion. The sarcopenia index is a promising surrogate marker of dynapenia and sarcopenia in patients with non-alcoholic fatty liver disease.
23 April 2024 in Russian Journal of Preventive Medicine
This literature review continues the paper, «Clinical consequences of sarcopenic obesity. Part 1. Non-alcoholic fatty liver disease, type 2 diabetes mellitus, chronic kidney disease» (Russian Journal of Preventive Medicine. 2024;27(8):114–120. (In Russ.). https://doi.org/10.17116/profmed202427081114), and describes the association of sarcopenic obesity with cardiovascular diseases and osteoporosis from the point of their prevalence in patients with sarcopenic obesity compared to obese patients without sarcopenia and/or the general population. The paper analyses possible pathophysiological mechanisms that cause the development of clinical consequences in sarcopenic obesity. Unlike primary or age-associated sarcopenia, which is more common in aged people, sarcopenic obesity (as a form of secondary sarcopenia) can develop at any age. Besides, the authors prove a higher prevalence of chronic non-infectious diseases in sarcopenic obesity and give reasons for unfavorable outcomes for patients. This evidences the need for active detection of sarcopenic obesity and additional examination of patients for timely detection of clinical consequences of this pathology. Such tactics can contribute to improving the health status of the working-age population and reducing costs related to providing medical care.